TEMPLATE LETTER TO PARLIAMENTARY CANDIDATES [Your address]

First Page		Document Content
Date: 2012-07-13 16:39:10 Triazines Azacitidine lactams Myelodysplastic syndrome National Institute for Health and Clinical Excellence Medicine Health Nucleosides		TEMPLATE LETTER TO PARLIAMENTARY CANDIDATES [Your address] Add to Reading List Source URL: mdspatientsupport.org.uk Download Document from Source Website File Size: 28,50 KB Share Document on Facebook

	Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma DocID: 15uOM - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION DocID: 13My6 - View Document
	June 14, 2013 Astex Pharmaceuticals Announces Presentation of Updated Results of SGI[removed]Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology As DocID: 11odm - View Document
	Abst. No. Outcomes of Intermediate or High Risk Myelodysplastic Syndromes (MDS) Patients Post Azacitidine and/or Decitabine Treatment Failures with SGI-110, a Novel Second Generation Hypomethylating Agent (HMA) DocID: 10gfI - View Document
	DNA demethylation activity over time and safety of 3 different dose-escalation regimens of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in the treatment of relapsed/refractory patients with MDS and AML DocID: Z1WQ - View Document